Kura Oncology, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a KURA research report →
Range $24 – $24
Price Chart
About the company
Kura Oncology, Inc. , a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s first commercial product, KOMZIFTI (ziftomenib), a potent, selective, reversible and oral small molecule menin inhibitor; Darlifarnib, a Phase 1 first-in-human FIT-001 trial which includes multiple cohorts to evaluate darlifarnib in combination with other targeted therapies in large solid tumor indications; and KO-7246, a next-generation menin inhibitor, for use in diabetes and cardiometabolic disorders and additional next-generation menin inhibitors for use in combination with other therapies in solid tumors.
- CEO
- Troy Wilson
- IPO
- 2015
- Employees
- 260
- HQ
- San Diego, CA, US
Get TickerSpark's AI analysis on KURA
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $634.88M
- P/E
- -2.23
- Fwd P/E
- 3.56
- PEG
- 0.07
- P/S
- 8.51
- P/B
- 36.76
- EV/EBITDA
- -2.22
- Div Yield
- 0.00%
- Gross Margin
- 98.45%
- Op Margin
- -394.32%
- Net Margin
- -369.26%
- ROE
- -336.24%
- ROIC
- -73.04%
Latest fiscal year · YoY change
- Revenue
- $67.48M+25.2%
- Gross Profit
- $67.42M+25.1%
- Op Income
- $-303,631,000
- Net Income
- $-278,666,000-60.2%
- EPS
- $-3.18-57.4%
- OCF Growth
- -147.7%
- FCF Growth
- -152.8%
- 52W High
- $13.90
- 52W Low
- $6.75
- 50D MA
- $9.77
- 200D MA
- $9.76
- Beta
- 0.38
- RSI (14)
- 36
- Avg Volume
- 2.10M
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Kura Oncology said Comzifti continued to gain commercial traction, while the company advanced a broader frontline/combination strategy for ziftomenib and secured FDA alignment for a registrational darlafarnib path.· November 10, 2026
- Comzifti net product revenue reached $13.9 million, up 53% sequentially, with new patient starts up 30% and total prescriptions up 65%.
- Management said Comzifti kept a majority share of menin-inhibitor new patient starts in relapsed/refractory NPM1-mutant AML and coverage now reaches nearly 100% of covered lives.
- Kura highlighted 8 ziftomenib abstracts at ASH, including 4 oral presentations and first clinical data in FLT3 combinations.
- The company announced FDA alignment on a single-arm monotherapy registrational study for darlafarnib in HRAS-mutant salivary gland cancer, with about 40 patients planned.
- Kura also closed a strategic financing with OrbiMed, adding $50 million of debt funding and a $5 million equity investment, with up to $300 million of potential funding overall.
Comzifti net product revenue was $13.9 million in Q3, compared with no product revenue in the third quarter of 2025, and it was up 53% sequentially. New patient starts were approximately 150, up about 30%, and total prescriptions were more than 2,400, up 65%. Collaboration revenue from the Kyowa Kirin partnership was $8.9 million versus $20.8 million a year ago. R&D expense was down 2% to $67 million, SG&A was down 8% to $30.2 million, and net loss decreased 5% to $70.2 million; share-based compensation in net loss was $8.2 million. On guidance, Kura updated collaboration revenue guidance to $40 million to $45 million and maintained guidance of $90 million to $110 million in each of 2027 and 2028. Management said September 30 cash, plus subsequent financing proceeds and about $180 million in anticipated Kyowa Kirin payments, should support the current operating plan beyond the initial ziftomenib top-line results expected in 2028.
Troy Edward Wilson framed the quarter as another step in building what he called leadership in AML, emphasizing both current commercial momentum and a push into earlier-line and combination settings. He said the company is heading into ASH with an unusually broad ziftomenib dataset, and he repeatedly stressed that combinations, frontline use, and FLT3 inhibitor combinations are central to Kura’s strategy. He also highlighted the FDA-aligned darlafarnib path and said the financing gives Kura flexibility to pursue what he described as a second potential precision-oncology product.
Jennifer Fulk said the balance sheet strengthened to support execution, with $492 million in cash, cash equivalents, and short-term investments at quarter-end. She said Kura raised about $32 million through the ATM during the quarter and renewed the ATM with $150 million of capacity, while the OrbiMed deal adds up to $300 million of potential funding, including $50 million of debt and a $5 million equity investment at close. She described the debt as a 7-year term with principal due at maturity and noted a modest single-digit cap royalty on U.S. Comzifti net sales. On the P&L, she cited $13.9 million of Comzifti revenue, $8.9 million of collaboration revenue, $67 million of R&D, $30.2 million of SG&A, and $70.2 million of net loss; she said the company will prioritize capital toward commercial growth and the highest-value milestones.
Analysts focused on repeat prescriptions, duration of therapy, and how much growth is coming from refills versus new starts; management said patients are getting on therapy and staying on therapy, but there is not yet enough mature data for a full duration readout beyond the roughly 5- to 6-month range they have guided to. Questions also centered on the J&J competitor abstract, and Troy argued that the headline data should be viewed in context, citing missing efficacy-evaluable patients and safety issues such as differentiation syndrome and QTc prolongation; he said Kura’s response is to keep pushing into frontline and combinations, where he believes ziftomenib is differentiated. On darlafarnib, management explained that FDA aligned on a full-approval path in a roughly 40-patient monotherapy study because of high unmet need, durable prior monotherapy signals, and the rarity of HRAS-mutant salivary gland cancer. There was also discussion of transplant dynamics, with management saying they are not seeing a major transplant-driven explanation for the quarter’s growth and instead see combination use and earlier treatment as the bigger levers.
The quarter showed clear commercial traction for Comzifti, with sequential revenue growth, rising new starts, and even faster growth in total prescriptions. Management sounded confident that the combination/frontline strategy is being validated by upcoming ASH data and by physician interest, and the company now has a second program in darlafarnib on a faster regulatory track. The OrbiMed financing and strong cash position also reduce near-term funding pressure.
The company still depends on execution in a competitive AML market, and management spent significant time defending ziftomenib against competitor data and safety concerns. Comzifti is still concentrated in the relapsed/refractory NPM1-mutant setting, so the bigger growth story depends on moving into frontline combinations and sustaining that build over time. Darlafarnib remains earlier-stage, and while the FDA path is clearer, the company still needs to prove the monotherapy study can deliver the response and durability needed for approval.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 97.2%
- Shares Outstanding
- 91.88M
- Float Shares
- 89.33M
of shares held by institutions
227 13F filers
Buy/sell ratio 0.50. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Congressional trading
Senate and House stock disclosures for KURA, newest first.
| Member | Type | Traded | |
|---|---|---|---|
| Chris JacobsHouse · NY27 | Buy | Dec 12, 22 | Filing → |
Source: public STOCK Act disclosures. Filed weeks after the trade — a lagging signal, not a real-time one.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Blackrock, Inc. | 10.51M | ▲ 871.70K |
| Montanova Capital, LLC | 8.58M | 0 |
| Bvf Inc/Il | 8.45M | 0 |
| Vanguard Group Inc | 5.51M | ▲ 39.10K |
| State Street Corp | 4.71M | ▼ 620.30K |
| Vanguard Capital Management LLC | 3.92M | ▲ 130.48K |
| Armistice Capital, LLC | 3.68M | ▼ 58.00K |
| Aqr Capital Management LLC | 3.13M | ▲ 1.00M |
| Geode Capital Management, LLC | 2.30M | ▲ 65.73K |
| Goldman Sachs Group Inc | 2.27M | ▲ 831.70K |
| Alethea Capital Management, LLC | 2.17M | ▲ 638.57K |
| Prosight Management, LP | 2.02M | ▼ 1.33M |
Held by 259 ETFs
Biggest fund positions in KURA by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Nov 19, 26 | Powl Brian T. | sell | 448 |
| Nov 16, 26 | DOYLE THOMAS JAMES | sell | 4,697 |
| Nov 16, 26 | Leoni Mollie | sell | 19,009 |
| Nov 17, 26 | Leoni Mollie | sell | 22,241 |
| Nov 16, 26 | Powl Brian T. | sell | 9,196 |
| Nov 17, 26 | Powl Brian T. | sell | 15,254 |
| Nov 16, 26 | Bair Teresa Brophy | sell | 8,601 |
| Nov 16, 26 | FORD KATHLEEN | sell | 7,042 |
| Nov 17, 26 | FORD KATHLEEN | sell | 3,668 |
| Nov 16, 26 | WILSON TROY EDWARD | buy | 101,119 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our KURA coverage
Recent articles, reports, and earnings notes.
No research on KURA yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate KURA report →Kura Oncology, Inc. (KURA) Presents at UBS Global Biopharma Conference 2026 Transcript
seekingalpha.com · Nov 17
Kura Oncology: Refills Drive Komzifti Launch, While Funding Bridge Sets The Pace
seekingalpha.com · Nov 17
Kura Oncology to Participate in Two Investor Conferences in November
globenewswire.com · Nov 13
Kura Oncology, Inc. (KURA) Q3 2026 Earnings Call Transcript
seekingalpha.com · Nov 11
Kura Oncology Q3 Earnings Call Highlights
marketbeat.com · Nov 10
Kura Oncology (KURA) Reports Q3 Loss, Beats Revenue Estimates
zacks.com · Nov 10
Kura Oncology Reports Third Quarter 2026 Financial Results and Corporate Update
globenewswire.com · Nov 10
Kura Oncology (KURA) Loses 35.4% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
zacks.com · Nov 6
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.